Huprine X
Latest Information Update: 10 Dec 2007
Price :
$50 *
At a glance
- Originator Mayo Clinic
- Class Antidementias; Neuroprotectants
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 10 Dec 2007 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
- 05 Oct 2001 New profile
- 05 Oct 2001 Preclinical development for Alzheimer's disease in USA (Unknown route)